Karyopharm Therapeutics (KPTI) PT Raised to $32 at Morgan Stanley
- Wall Street ends sharply lower in broad sell-off
- China Property Titan Evergrande (EGRNF) Collapses to 11-Year Lows, Analysts Wary of Domino Effect
- Apple (AAPL) iPhone 13 Has Strong Start with Positive Mix Skew - JP Morgan
- Lennar (LEN) Falls as Reported Q3 Revenue Beats, EPS Slightly Missed Estimates
- Royal Dutch Shell to Sell its Permian Business to ConocoPhillips (COP) for $9.5 Billion Cash
Morgan Stanley analyst David Lebowitz raised the price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $32.00 (from $31.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Goldman Sachs Downgrades Kingsoft Corp Ltd. (3888:HK) (KSFTF) to Neutral
- Tullow Oil Plc. (TLW:LN) (TUWOY) PT Raised to GBP0.55 at Berenberg
- GlaxoSmithKline (GSK:LN) (GSK) PT Lowered to GBP14.60 at UBS
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!